Last Updated on September 5, 2021 by The Health Master
Granules India yesterday said it has received licence from Defence Research and Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG).
Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, Granules India said in a filing to BSE.
“Granules is working closely with DRDO team to launch the product in India at the earliest,” it added.
The drug reduces a patient’s average recovery time by two and half days and oxygen demand by up to 40 per cent, the filing said.
Govt amends New Drugs & Clinical Trial Rules 2019
NPPA panel recommends 15% rise in ceiling price for 3 formulations
DCGI gives nod for Vaccine’s phase-II/III trials on kids aged between…
Kudos to Gujarat FDCA for Covaxin facility: Bharat Biotech
How to test if green labelled package is pure veg? High…
Latest Notifications regarding Pharmaceuticals